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Abstract
Objective The purpose of this review is to summarize the
research regarding Human Papillomavirus (HPV) vaccination
uptake among families with adolescent/preadolescent
daughters. Methods Literature searches (utilizing PubMed
and PsychInfo databases) were conducted and research
examining psychological and environmental factors which relate
to HPV vaccine uptake and intentions was
reviewed. Results Factors such as physician
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recommendations, perceptions of the beliefs of peers and
significant others, history of childhood immunizations, and
communication with adolescents regarding sexual topics appear
to influence HPV vaccination outcomes. Conclusions 
Although primary prevention of cervical and other cancers is
available for preadolescent and adolescent girls, rates of HPV
vaccine uptake are low. Future interventions should target
vaccine intent and physician/family communication as a means
to increasing HPV vaccination.
Introduction
Genital human papillomavirus (HPV) is the most common sexually
transmitted infection (STI; Weinstock, Berman, & Cates, 2004).
Epidemiological studies indicate that ∼50–70% of sexually active women
contract HPV at some point during their lifetime (Mariam, 2005). Human
papillomavirus infection rates are highest in younger women and rise
sharply soon after the median age of first sexual activity—16.9 years for
females (Wulf, 2002). More specifically, the prevalence of HPV has been
estimated to be as high as 39.6% among 14–19-year olds and 49.3% among
20–24-year old sexually active females (Dunne et al., 2007). The United
States Youth Risk Behavior Surveillance of 2007, a national school-based
survey of health-risk behaviors among high school students, reports that
45.9% of female students have ever engaged in sexual intercourse (Eaton et
al., 2008). Women who begin having sex at young ages, have more sexual
partners, and engage in more unprotected sex are at increased risk for HPV
[American Cancer Society (ACS), 2008b; Burchell, Winer, de Sanjose, &
Franco, 2006].
Of the over 100 identified types of HPV, ∼40 strains affect the genital tract
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(Markowitz et al., 2007). Furthermore, oncogenic HPV strains have been
linked to cervical, vaginal, vulvar, penile, and anal cancers. Cervical cancer
is the second most common cancer among women worldwide and is the
leading cause of cancer-related deaths among women in developing
countries (Bosch & de Sanjose, 2003; Parkin, Bray, Ferlay, & Pisani, 2005).
The ACS estimated that in the United States alone 11,070 women would be
diagnosed with cervical cancer in 2008, and that 3,870 deaths occurred
secondary to cervical cancer (ACS, 2008a). Screening for cervical cancer is
conducted via Papanicolaou (Pap) testing to identify abnormal cells in the
cervix that may lead to cancer. Approximately 55 million Pap tests are
performed each year in the United States, and of these ∼3.5 million (6%)
yield abnormal results which require medical follow-up (National Cancer
Institute, 2007). Some HPV infections may be asymptomatic and most
infected women have normal Pap test results, as the infection clears without
incident.
Although most HPV infections are transient (i.e., will resolve on their own
within 1–2 years), persistent HPV infection is a necessary cause of cervical
cancer (Ault, 2007), because 100% of cervical cancers are HPV related
(Waggoner, 2003; Walboomers et al., 1999). In particular, HPV types 16
and 18 are responsible for 70% of cervical cancers (Paavonen & Lehtinen,
2008). It is estimated that the slow progression of abnormal cell growth due
to HPV infection leading to cervical cancer may take 10–15 years
(Association of Reproductive Health Professionals, 2005). Thus, although
HPV is contracted most often in sexually active adolescents and women
aged 15–24 years, cervical cancer diagnosis most often occurs in women
over the age of 40, with median age at diagnosis being 48 years (“SEER
Cancer Statistics Review, 1975–2003, National Cancer Institute”, 2006).
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Recent cancer prevention efforts have led to the development of a vaccine
against HPV, which is currently available and has been demonstrated to be
safe and clinically effective (Harper et al., 2006; Koutsky & Harper, 2006;
Markowitz et al., 2007). Specifically, in June 2006, the U.S. Food and Drug
Administration (FDA) approved a quadrivalent HPV vaccine (i.e., Gardasil
produced by Merck & Co., Inc.) designed to protect young women from the
four types of HPV (6, 11, 16, and 18) which account for 70% of cervical
cancers and 90% of genital warts cases (FDA, 2006a; Villa et al., 2005). In
clinical trials, the quadrivalent HPV vaccination demonstrated nearly 100%
efficacy in protecting females against these four HPV types (Villa, 2007).
Although a bivalent HPV vaccine (i.e., Cervarix manufactured by
GlaxoSmithKline) is expected to be approved by the FDA for use in the
USA in late 2009, our discussion will focus on the quadrivalent HPV
vaccine.
The present review evaluates existing literature on factors influencing
familial decision making regarding HPV vaccination. It is important to
understand and utilize these factors in developing interventions for
vaccination uptake. Because the vaccine is relatively new, little is known
about the complexity of familial and other factors that may affect vaccine-
related decision making. Previous studies have examined attitudes toward
HPV immunization and concluded that a greater understanding of the
complicated decision-making process for families to vaccinate is needed, as
it involves sensitive issues including vaccination history, physician
negotiation, and adolescent sexual behavior. Insight into the parental
decision-making process regarding HPV vaccination may be found in
previous research addressing childhood vaccinations and adolescent sexual
behavior. This article is organized into three sections. First, we describe
HPV vaccination in terms of indication and administration, impact on
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cervical cancer outcomes, importance for high risk populations, and current
uptake. Next, factors that influence familial decision making regarding HPV
vaccination are identified in the context of childhood vaccination and
adolescent sexual health literatures. Finally, future directions for
maximizing HPV vaccination uptake are presented.
HPV Vaccination
Indication and Administration
Routine HPV vaccination is recommended by the Advisory Committee on
Immunization Practices (ACIP) for adolescent females aged 11 and 12
years, though the series of three injections administered over 6 months can
be started as young as 9 years of age (Markowitz et al., 2007). The FDA has
approved the quadrivalent HPV vaccine for girls and women between the
ages of 9 and 26 years, as vaccine administration is recommended prior to
sexual onset (FDA, 2006b). Vaccination is also recommended for those aged
13–26 years who have not been vaccinated or completed the 3-shot vaccine
series (Markowitz et al., 2007). In addition to the importance of targeting
sexually naïve preadolescents and adolescents for routine HPV vaccination,
age at vaccination was demonstrated to be inversely related to anti-HPV
immune response (Giuliano et al., 2007). Transmission of HPV primarily
occurs via vaginal and anal intercourse. Oral and digital infection with
genital HPV strains also occurs; however, the risk of transmission by
digital–genital or oral–genital contact appears minimal (Burchell et al.,
2006). Nevertheless, evidence is mounting to support the association of
orally transmitted HPV infection with head and neck squamous cell
carcinomas, and oropharyngeal cancer in particular (Gillison et al., 2000;
Gillison & Shah, 2001; Hennessey, Westra, & Califano, 2009), as risk for
oral and genital HPV infection increases with greater numbers of lifetime
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oral and vaginal sexual partners (D’Souza, Agrawal, Halpern, Bodison, &
Gillison, 2009).
Impact on Cervical Cancer Outcomes
Because the prophylactic quadrivalent vaccine only protects against four
HPV types and is not therapeutic (does not treat HPV infections or cervical
cancer), it alone will not eliminate cervical cancer. Therefore, continued
cervical cancer screening is recommended (Harper & Paavonen, 2008). The
projected benefits of mass HPV immunization are considerable, as the ACS
estimates a potential reduction of cervical cancer risk by 70% with the
vaccine’s use over many decades (Saslow et al., 2007). Such a decline in
cervical cancer rates will depend on the number of carcinogenic HPV types
targeted by the prophylactic vaccine, durability of protection, degree of
vaccination coverage of the at-risk population, and whether the medical
community and the public continue to follow recommended screening
guidelines (Saslow et al., 2007). Therefore, promotion of HPV vaccine
uptake is critical.
Importance for High-risk Populations
Of particular importance is vaccination among immunocompromised groups
at high risk for HPV-related complications [e.g., human immunodeficiency
virus (HIV)-infected youth, organ transplant recipients, pediatric survivors
of Hodgkin’s lymphoma, or childhood cancer survivors who received
hematopoietic stem cell transplantation or pelvic irradiation]. See the
“Future Directions” section of this manuscript for an expanded discussion of
the HPV vaccine and its implications for pediatric high-risk populations.
Estimates of Current Uptake
There is a growing literature on the implementation of the HPV vaccine,
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including the many factors contributing to a family’s decision to vaccinate a
daughter. Numerous clinical trials were conducted prior to the quadrivalent
HPV vaccination’s approval by the FDA, and at least 21,000 females were
vaccinated over four clinical trials (FDA, 2006a). Currently, more than 7
million doses have been distributed [Centers for Disease Control and
Prevention (CDC), 2007a]. One of the first studies to estimate rates of HPV
vaccination among sexually experienced females aged 13–26 years found
that only 5% of participants had received at least one HPV vaccine dose
(Kahn, Rosenthal, Jin, Huang, Namakydoust, & Zimet, 2008). In October
2008, the CDC published results from the 2007 National Immunization
Survey—Teen (NIS-Teen) stating that 25% of U.S. females aged 13–17
years initiated the HPV vaccine series, translating into ∼2.5 million girls
(CDC, 2008). Additionally, 66% of participants in the former study reported
intentions to initiate the vaccine; however, 68% of these participants tested
HPV-positive (Kahn, Rosenthal, Jin, Huang, Namakydoust, & Zimet, 2008).
Regardless, these rates of vaccine initiation are significantly lower than the
goal proposed by the Healthy People 2010 initiative to increase vaccination
coverage levels for adolescents aged 13–15 years of age to 90%.
Influences on HPV Vaccination Decisions
Physician Recommendations
Health care professionals’ (pediatricians’ as well as
obstetrician/gynecologists’) recommendations for HPV vaccination are
likely to influence both parent and adolescent decision making in regard to
receiving the vaccine (Zimet, Mays, & Fortenberry, 2000). Adolescents are
more likely to be seen by a pediatrician than any other health care provider,
and medical providers have considerable influence on their patients’
immunization decisions (Zimet, Mays, Winston, et al., 2000; Ziv, Boulet, &
7
Slap, 1999). Pediatrician attitudes and intentions of recommending HPV
vaccination appear to promote successful immunization delivery (Daley et
al., 2006). Immunization recommendations have been shown to be
influenced by personal and professional characteristics (e.g., age, practice
location, HPV knowledge, beliefs about patients’ sexual experience/history,
comfort in discussing sexual behaviors, beliefs regarding impact of
immunization on adolescent sexual behaviors), office procedures (e.g.,
vaccinating children during sports physicals, ill visits, reminder calls), and
vaccine cost and reimbursement (Kahn et al., 2005; Kahn et al., 2007). An
additional influence is parental factors, such as vaccination requests, denial
that child is at risk, concerns regarding vaccine safety and riskier adolescent
behaviors, reluctance regarding STI immunization and sexuality discussion
with child, and the belief that child receives too many vaccines (Daley et al.,
2006; Kahn et al., 2005; Kahn et al., 2007). Pediatrician intention to
recommend HPV vaccination has been found to be higher for adolescents
who were older and female (Kahn et al., 2005). Additionally, there is
evidence that pediatricians are less likely to recommend vaccination when
they are male, uncomfortable discussing sexuality issues with female
patients, and not in the practice of prescribing oral contraceptives (Daley et
al., 2006).
Intention to recommend is a powerful predictor of actual recommendation
behavior. In a study undertaken prior to licensure of an HPV vaccine, 10%
of pediatricians surveyed reported being unlikely to recommend HPV
vaccination to patients of any age; and although 90% of providers would
recommend the vaccine, only 46% of sampled pediatricians anticipated
administering the HPV vaccine to the targeted age group of 10–12-year-old
females (Daley et al., 2006). Pediatricians’ intention to recommend HPV
vaccination appears also to be influenced by endorsement of vaccination
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practices by nationally recognized advisory groups. For example, in a study
of HPV immunization and intention to recommend, nearly all surveyed
providers indicated intentions to follow immunization recommendations of
the ACIP (94.5%), CDC (98%), and American Academy of
Pediatrics/Redbook (99.8%); however, the study did not assess the number
of pediatricians who actually have recommended the HPV vaccine (Kahn et
al., 2005).
Parental Attitudes toward Vaccination
Parental attitudes are key to understanding HPV vaccination outcomes. Prior
to HPV vaccination approval and soon thereafter, parents demonstrated a
poor understanding of HPV (i.e., were not well informed of a vaccine for the
virus, reported little or no knowledge of HPV, and were unaware of the
associations of HPV with Pap testing and with cervical cancer); however,
parents reported high levels of interest in STI/HPV vaccination for their
adolescents (Brewer & Fazekas, 2007; Zimet, Liddon, Rosenthal, Lazcano-
Ponce, & Allen, 2006). A number of factors have been evaluated with regard
to parental support for/resistance to HPV immunization. Parent socio-
demographic variables including ethnicity, age, education, and religion do
not appear to be correlated with acceptance of HPV vaccination (Brabin,
Roberts, Farzaneh, & Kitchener, 2006; Marlow, Waller, & Wardle, 2007a),
although preliminary reports suggest that African-American caregivers may
be less aware of and informed about HPV vaccination than Caucasian
caregivers (Ragin et al., 2009). Conversely, other medical and demographic
factors (e.g., history of HIV testing, having an older daughter, higher
number of lifetime sexual partners) as well as socio-environmental factors
(e.g., having had a family member with cancer, belief that the vaccine would
be accepted by peers/partners) are associated with acceptance of HPV
vaccination (Gerend, Lee, & Shepherd, 2007; Kahn, Rosenthal, Hamann, &
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Bernstein, 2003; Marlow et al., 2007a). In a study conducted by Slomovitz
and colleagues (2006), the majority of women surveyed were accepting HPV
vaccine for themselves and their children. A history of abnormal Pap test
was not shown to be related to the women’s acceptance of the HPV vaccine
for either themselves or their children; however, mothers’ willingness to
vaccinate offspring against HPV was associated with their willingness to
obtain the vaccination themselves and with whether their children had
received all previously recommended immunizations. A greater belief in the
protection of childhood vaccines in general, as well as greater belief in the
protection offered by HPV vaccination, have been found to be correlated
with HPV vaccine acceptability for both sons and daughters (de Visser &
McDonnell, 2008). Perceived physician encouragement, HPV-related
knowledge, and other parental Health Belief factors also appear to be
associated with a positive parental attitude toward immunization (Brewer &
Fazekas, 2007).
In contrast, parental anxiety regarding vaccine safety, conservative
religious/cultural views, belief that vaccination encourages sexual activity,
specific HPV vaccine and general vaccine matters, moral issues about
sexuality, denial of daughter’s risk status, lack of disease-specific
knowledge, risk of unknown harmful side effects, and low concern for
child’s HPV acquisition have characterized the opposition that some parents
have to HPV vaccination (Brabin et al., 2006; Brewer & Fazekas, 2007;
Constantine & Jerman, 2007; Mays, Sturm, & Zimet, 2004; Slomovitz et al.,
2006). Mothers who have delayed, refused, or regretted a previous pediatric
immunization have also been reportedly less inclined to accept HPV
vaccination (Marlow, Waller, & Wardle, 2007b). Although HPV vaccination
acceptance is high among parents, mothers have endorsed the belief that
vaccination will result in risk compensation (i.e., increased risky sexual
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behavior), which may predict non-acceptance of HPV vaccination (Marlow,
Forster, Wardle, & Waller, 2009).
Parent–child communication regarding adolescent protective sexual health
is an important component of parental consideration of HPV immunization,
as parents who discussed the HPV content with their children are more
likely to support vaccination (Brabin et al., 2006). Furthermore, mothers
willing to discuss cervical cancer, sex, STIs, or HPV with their daughters at
earlier ages are more likely to accept HPV vaccination and have been shown
to be in favor of early age vaccination (Marlow et al., 2007a). Parents
finding it difficult to discuss sex with their children were least likely to
agree with HPV vaccination (Brabin et al.). Furthermore, it has been
reported that mothers are prepared to discuss the HPV vaccine when
discussing cervical cancer, though would not discuss HPV or STIs until their
daughters were older. This suggests that some mothers prefer to explain
HPV vaccination as one “against cancer” and avoid details about protecting
against STI infection until the child is older (Marlow et al., 2007a). It may
be important to examine whether a child’s age influences the occurrence
and/or content of parental communication about sex and subsequently
family decisions regarding HPV vaccination. What parents tell their
children and adolescents about HPV and its vaccination is likely to be a
function of the child’s developmental level.
Adolescent Attitudes toward Vaccination
As the familial decision to obtain HPV immunization involves adolescent
perceptions as well as parental factors, and because it is recommended that
health care decisions for older children and adolescents strive for assent of
the patient in addition to parental and physician participation (Committee
on Bioethics, 1995; Constantine & Jerman, 2007), the effectiveness of
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cervical cancer prevention will rely on improving cancer-related knowledge
among adolescents. Many young women have never heard of cervical
cancer, and limited knowledge about HPV symptoms and Pap testing has
been noted among adolescents (Dell, Chen, Ahmad, & Stewart, 2000; Mays
et al., 2000; Mosavel & El-Shaarawi, 2007). Adolescent knowledge of HPV
appears to be influenced by physicians and health educators, peer groups,
and media. Young women familiar with HPV and the vaccine have reported
receiving their information at school, from a doctor, and/or via television
(Hoover, Carfioli, & Moench, 2000), with most receiving information from
school classes and media sources (Dell et al., 2000).
Current research on adolescent attitudes regarding HPV immunization
separate from parental attitudes is limited in scope, perhaps reflecting the
dominant role of parents in the vaccination decision. Adolescents often
contribute to the familial decisions regarding HPV vaccination, and
adolescent attitudes have been found to be similar to those of their parents
regarding vaccine efficacy, the influence of recommendations by health care
professionals, and consideration of vaccine cost (Zimet, Mays, Winston, et
al., 2000). Studies on adolescent acceptance of STI vaccination have shown
high levels of acceptance, with acceptance influenced by perceptions of
vaccine characteristics (cost, efficacy), adolescents’ health beliefs, provider
recommendations, increased perceived susceptibility to STIs such as HIV,
and perceived benefits of immunization (Rosenthal, Kottenhahn, Biro, &
Succop, 1995; Zimet, Blythe, & Fortenberry, 2000; Zimet, Fortenberry, &
Blythe, 1999; Zimet, Mays, Winston, et al., 2000). In contrast, greater
perceived obstacles (e.g., difficulty keeping clinic appointments), fear of the
vaccine causing infection, low perception of risk, and fear of needles have
been found to be related to lower acceptability of a vaccine for STIs (Zimet
et al., 1999).
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Although adolescents report high levels of acceptance, HPV vaccination
intentions, self-efficacy (or belief in their ability to initiate vaccination),
and actual vaccination rates are reportedly low (Kahn, Rosenthal, Jin,
Huang, Namakydoust, Rosemore et al., 2008). In addition to health beliefs,
history of pregnancy and consistent condom use have been associated with
adolescents’ intent to receive the vaccine, whereas correlates of higher self-
efficacy to initiate vaccination have included insurance coverage, history of
STI, fewer perceived barriers to vaccination, higher perceived severity of
HPV, and current smoking (Kahn, Rosenthal, Jin, Huang, Namakydoust,
Rosemore et al., 2008; Kahn, Rosenthal, Jin, Huang, Namakydoust, &
Zimet, 2008). Although parents may have concerns about vaccinating before
sexual debut, 90% of adolescents and young women have reported that the
best time for females to receive HPV vaccination is before becoming
sexually active (Hoover et al., 2000).
Adolescent Vaccination Completion
Studies assessing maternal and adolescent correlates of HPV vaccination
completion have focused primarily on demographic factors and have found
that lower maternal education, increased patient age and grade level, along
with residing in a northern region of the USA, all related to increased
vaccine completion (Rosenthal et al., 2008; Vanable, Carey, Brown,
Bostwick, & Kraus, 2009). As mentioned above, results from an earlier
study (Slomovitz et al., 2006) indicated that mothers’ history of abnormal
Pap results was not associated with the fact that they were accepting HPV
vaccine for themselves and their children; on the other hand, in a more
recent study, maternal health factors associated with daughters’ HPV
vaccine initiation included history of cervical cancer screening and
abnormal Pap test result or STI (Chao, Slezak, Coleman, & Jacobsen, 2009).
Among adolescents, greater knowledge, being sexually active, and greater
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health care provider trust have been associated with increased rates of
vaccination (Vanable et al., 2009). In a qualitative study comparing reasons
why mothers do or do not vaccinate their adolescent daughters for HPV,
lack of knowledge about HPV, age-related concerns, and low perceived risk
of infection were commonly cited reasons for declining vaccination;
whereas desire to prevent illness, physician recommendation, and a high
perceived risk of infection were commonly identified motivating factors
(Dempsey, Abraham, Dalton, & Ruffin, 2009).
Decision Making Regarding Childhood Vaccination
It is helpful to investigate family decision making toward general childhood
immunizations in order to understand the decision to obtain the HPV
vaccine in particular. Factors such as health care providers’ attitudes and
recommendations, as well as parent and adolescent beliefs and attitudes
remain consistent domains of influence across the general vaccination
literature (Sturm, Mays, & Zimet, 2005). Decisions to immunize one’s child
may also be influenced by social-environmental factors (e.g., cultural
beliefs), and parent-specific or personal factors (e.g., perceptions of
susceptibility). Additional influences on decision making are familial
interface with the health care system (e.g., health care provider
attitudes/recommendations), institutional policies and interventions related
to vaccines (e.g., federal and states mandates for school enrollment), media
influences, peer norms, as well as the physical environment of health (e.g.,
background prevalence of a vaccine-preventable disease; Sturm et al.,
2005). Parents’ acceptance of general childhood vaccines may be influenced
by inaccurate beliefs, such as the worry that the measles, mumps, and
rubella (MMR) vaccine causes autism that has led some parents to question
whether to vaccinate their children. Additionally, vaccines have sometimes
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been considered only partially successful, as parents cited susceptibility to
chickenpox following vaccination as contradiction of vaccine utility (Keane
et al., 1993). In order to achieve HPV vaccine acceptance among parents and
adolescents, it is necessary to evaluate current perceptions of vaccine
effectiveness and provide accurate HPV-specific educational information
because HPV vaccine acceptability is influenced by the same theoretical
constructs that have been crucial to the uptake of other vaccines (Brewer &
Fazekas, 2007).
Sexual Communication
Decisions to vaccinate against a STI are influenced by parental and
adolescent attitudes toward sexual behavior, because beliefs about
adolescent contraception use, as well as parent–child sexual communication,
may affect familial vaccination decisions. Mothers have been found to be
the primary communicators with adolescents on sex-related topics, and to be
more likely to discuss sexual matters with daughters than with sons.
Furthermore, mother–daughter pairs are more likely to discuss topics such
as birth control, reproduction, physical and sexual development, and sexual
pressures, than HIV or AIDS and choosing a sexual partner (Miller,
Kotchick, Dorsey, Forehand, & Ham, 1998). This may have important
implications for evaluating HPV vaccine decision-making processes within
the family, considering vaccination in the USA is currently only approved
for females. Also, it is possible that maternal, as opposed to paternal,
messages are most relevant.
Parents who communicate more openly with their adolescents regarding
sexual topics are more likely to discuss the use of contraceptives, and it is
crucial to examine what influences parents to discuss sexual topics since
HPV is acquired via sexual behavior. Self-efficacy, beliefs about
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contraception and sexuality, child’s age, and accurate knowledge appear to
influence parental engagement in discussions of sex-related topics with
adolescents. Parent–child communication on sexual topics may be
influenced by factors such as parents’ skill, comfort, and openness in
discussing sexuality; thus, many parents have reported feeling
uncomfortable discussing sexual topics with their teens, particularly parents
unfamiliar with medically accurate information (Jaccard, Dittus, & Litardo,
1999; McNeely et al., 2002; Whitaker, Miller, May, & Levin, 1999). Similar
to concerns about condoning HPV vaccination, some parents have been
reluctant to discuss the option of birth control with their adolescents for fear
that approval of birth control will encourage adolescents to engage in sexual
activity (Jaccard & Dittus, 2000); however, school-based sexual education
program’s safer sex educational components have not been shown to
increase sexual activity (Kirby & Coyle, 1997). In other cases, parents may
discuss various sexuality topics, but wait until they believe their teen has
been romantically involved, missing important opportunities to influence
behavior prior to sexual debut (Eisenberg, Sieving, Bearinger, Swain, &
Resnick, 2006). When children are older and more physically developed, it
is more likely that a discussion regarding safe sex practices will take place
(Lefkowitz, Boone, Au, & Sigman, 2003). Parents’ decisions for whether to
vaccinate against a STI such as HPV may involve fear of increased risky
sexual behavior and involve waiting until a teen is already at risk, not unlike
findings from research on parents determining whether to discuss or
approve contraception for their adolescent.
With regard to concerns about increased adolescent sexual behaviors if
vaccinated for HPV, the adolescent sexual health literature emphasizes the
importance of communication within families regarding topics of sexual
behavior, because communicating with one’s children regarding safe sexual
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practices has been shown to influence teens’ sexual behaviors. Higher levels
of sexual communication between parents and teens have been associated
with stronger beliefs regarding the effectiveness, safety, and usability of
condoms and oral contraceptives (Swain, Ackerman, & Ackerman, 2006).
Discussion regarding condom use are particularly relevant for HPV
prevention since condom use has been shown to effectively reduce the risk
of male-to-female genital HPV transmission (Epstein, 2005; Winer et al.,
2006). Early maternal discussions about safe sexual practices promote
condom use at first intercourse, and thus subsequent condom use, and
emphasis should be placed on receiving information about contraception
prior to initiating sexual intercourse (Miller, Levin, Whitaker, & Xu, 1998).
Given that there is an intrinsic adolescent sexuality component to HPV
vaccine utilization, comprehensive examination of influences on familial
decision to vaccinate for HPV must consider parental demographics,
efficacy beliefs, and parent–adolescent communications involving sexual
health behaviors.
Future Directions
Findings from this review reveal factors that contribute to parental decisions
regarding adolescent HPV vaccination including physician
recommendations, history of obtaining other recommended childhood
immunizations, and communication with adolescents regarding sexual
topics such as contraception. Perceptions of being at-risk for HPV,
perceived benefits of immunization, vaccine efficacy, and beliefs that
significant others would approve, appear to meaningfully sway adolescent
decisions on HPV immunization. This review emphasizes the need to
develop interventions to increase HPV vaccine uptake by identifying risk
factors which could be modified via intervention.
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Prospective interventions should aim to educate parents and adolescents on
the health benefits of HPV vaccination. Specific benefits of such
immunization include a clinically acceptable safety profile, high efficacy
against disease caused by the vaccine types, and widespread use of a
prophylactic HPV vaccine that could reduce lesions and cancers caused by
HPV (Dunne, Datta, & Markowitz, 2008; Harper et al., 2006). By addressing
patient knowledge levels, physicians may no longer perceive negative
parental reactions as barriers to vaccination of the targeted age group.
Though adolescents’ independent requests for HPV vaccination are
important to consider, because the recommended age for vaccination is
considerably younger than the age at which an adolescent would seek health
care on her own, HPV vaccination decisions are likely primarily driven by
parents, with daughters contributing to such health decisions differentially
based on their age and development. Research suggests that parents favor a
joint decision with their child on whether to receive the vaccine (Brabin et
al., 2006), and it has been recommended that the vaccine be offered when
adolescents can participate in the immunization decision based on their
developmental level (Olshen, Woods, Austin, Luskin, & Bauchner, 2005).
Future research should also focus on understanding the factors which relate
to HPV vaccination particularly among high-risk populations such as those
who are immunocompromised or are less likely to engage in cervical cancer
screening. As a result, study of HPV vaccine acceptability and completion is
needed among childhood and young adult cancer survivors with altered
immunity outcomes post treatment (particularly those treated with
hematopoietic stem cell transplantation or pelvic irradiation and those
diagnosed with Hodgkin’s lymphoma), because impaired immune function
is responsible for the increased rates of cervical and oral dysplasia
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experienced by these groups (Klosky et al., 2009). Those with HIV are also
at increased risk for HPV-associated malignancies, are more frequently
diagnosed with advanced and difficult-to-treat cervical cancers, and are
more likely to experience recurrence after treatment (Di Stefano et al.,
2006; Hagensee, Cameron, Leigh, & Clark, 2004; Sirivongrangson et al.,
2007). Likewise, young women who have undergone renal, liver, or lung
transplantation are at increased risk for HPV-related genital and oral
disease, including cancer (Courtney, Leonard, O’Neill, McNamee, &
Maxwell, 2009; Rose et al., 2006).
In addition to increased medical risk for HPV-related susceptibility and
complication experienced by these pediatric groups, behavioral and
cognitive indicators also contribute to their high-risk profile. After adjusting
for age, ethnicity, education, income and health insurance, women surviving
childhood cancer have been found to be significantly less likely than their
healthy siblings to have undergone a Pap smear within the previous three
years (Yeazel et al., 2004). It has also been suggested that survivors who
perceive themselves to be infertile as a result of cancer therapy may engage
in riskier sexual behaviors, which in turn, increases HPV exposure risk
(Zebrack, Casillas, Nohr, Adams, & Zeltzer, 2004). Similarly, some HIV-
infected youth have been reported to continue to engage in risky behaviors,
including unsafe sex, following a diagnosis of HIV (Diamond & Buskin,
2000).
Cognitive declines are associated with HIV infection (Smith et al., 2006)
and cancer treatment, and have been considered as contributors to riskier
sexual behaviors and HPV acquisition. For example, up to 40% of survivors
of childhood cancer have neurocognitive deficits, with inattention and
hyperactivity being among the most commonly reported late effects of
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treatment (Moleski, 2000; Mulhern, Fairclough, & Ochs, 1991). In the
general population, evidence exists linking inattention and/or hyperactivity
to increased risky sexual behavior, including earlier initiation of sexual
activity and intercourse, increased number of sexual partners, increased
casual sexual encounters, and increased partner pregnancies (Flory, Molina,
Pelham, Gnagy, & Smith, 2006). Based on this risk profile, the Children’s
Oncology Group’s Long-Term Follow-Up Guidelines for Survivors of
Childhood, Adolescent and Young Adult Cancer Version 3.0 (which serves
as the gold standard in the screening for late effects that may arise due to
treatment of pediatric cancer) has recommended HPV vaccination for all
eligible females surviving childhood cancer (American Academy of
Pediatrics Section on Hematology/Oncology Children’s Oncology Group,
2009).
Conclusion
Vaccination against HPV has the potential to significantly reduce lifetime
risk of cervical cancer (CDC, 2007b; Goldie et al., 2004; Sanders & Taira,
2003). Primary prevention of cervical and other cancers associated with
HPV is best achieved if vaccination occurs before sexual debut, because
HPV is sexually transmitted and often acquired soon after onset of sexual
activity (CDC, 2007b). Physician recommendations, parental and adolescent
health beliefs, perceptions of significant others’ and peer approval, history
of childhood immunizations, and parental communication with adolescents
regarding sexual topics have been found to be influential in familial
decision making regarding HPV immunization. Although the endorsement
of the HPV vaccine by national advisory groups is an important first step,
HPV vaccination remains underutilized. Interventions are needed to
translate these recommendations into a successful HPV vaccination
20
strategy.
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